EXOME

all the information, none of the junk | biotech • healthcare • life sciences

What's Hot in Boston Biotech

What's Hot in Boston Biotech

What are you looking forward to, CAR-T?
Nah, gene therapy of course.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

J&J Innovation’s Marian Nakada (left) hanging with some of our attendees as an onlooker anxiously spots the line for coffee.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Smile fellas, you’re now part of the slideshow.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

This is what’s known as a pre-event schmoozefest.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Yep, caught by our sneaky photographer.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Samantha Singer (The Broad Institute) and Matt Ottmer (Biogen) smile for the camera.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Alright, it's showtime.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Clare Midgley of the Broad Institute kicked things off with some remarks about the Broad’s mission.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Standing room only for our CAR-T talk (if you squint you can see Unum Therapeutics CEO Chuck Wilson and Fidelity Biosciences partner Ben Auspitz)

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

As these attendees (including Flagship Ventures CEO Noubar Afeyan, middle) can attest, bring a pen and notepad.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Or a laptop.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Alexis Borisy: Foundation Medicine chairman, and fedora aficionado.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

When Susan Lindquist first asked Tony Coles to lead the company based on her research (now known as Yumanity Therapeutics), he declined. But Coles soon became enamored with the science, and the challenge. ““When I die, what will be on my tombstone, will it be that I held some great jobs? Or that I wanted to make a difference?”

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

One of the points Vertex Pharmaceuticals's David Altshuler (right) made is that many of the clinical failures of the past decade weren’t an indictment of genomics---they were projects from the 90s, before the Human Genome Project. “Go look at what those projects were. What were they based upon? What was the logic? They were from a previous era,” he said.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Got questions? We’ll give you some time.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

And, in some cases, a microphone.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Jim Collins (left) and Amir Nashat (right) gave a realistic view of what synthetic biology has, and hasn’t yet accomplished---and the mistakes the field made in the past. “It’s a cautionary tale for investors,” Collins said. “You’ve got to do your due diligence.”

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Borisy said there is a “revolution” underway in how clinical trials are being run, both in the U.S. and abroad. He noted the “Lung Cancer Master Protocol,” a collaborative, multi-drug cancer study with a single control arm. “This is a radical proposition,” he said. “There are multiple of these getting underway.”

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

J&J's Marian Nakada (right) and PureTech’s Bernat Olle (left) spoke about how relationships and trust were some of the key factors that led to the January deal between Vedanta Biosciences and J&J.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Steve Paul acknowledged that gene therapy, despite its progress, is still in its early days. So is his company, Voyager Therapeutics---which is 14 months old yet is now poised for an IPO, as we wrote yesterday.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

This biotech is serious stuff.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Peter Kolchinsky posed a few provocative questions. One of them was whether gene therapy companies might be forced to address more difficult biological problems if carrier testing is broadly adopted. (OvaScience CEO Michelle Dipp, at right, moderated the gene therapy panel featuring Kolchinsky).

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

While things look great for Boston biotech, Noubar Afeyan warned attendees that the good times might not continue. Affordable lab space is disappearing. The local scene must continue to grow to compensate.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Wilson and Auspitz traded perspectives on the entrepreneur and investor point of view on CAR-T, a form of cancer immunotherapy that’s produced very exciting, yet early clinical results.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Alright enough of that science mumbo-jumbo. Let’s network.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

So, let’s figure out how to fix that lab space problem.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

New connections and re-connections are made.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Beers, bowties, and biotech.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

These two are either approving of the water or the content. I’m going with the content.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Attendees had the option of mingling, or staring at the hypnotic eye puzzle on TV in the background.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Some life lessons were dispensed after all the scientific lessons in the Broad’s auditorium.

photo ©KeithSpiroPhotography

What's Hot in Boston Biotech

What's Hot in Boston Biotech

Who said science geeks don’t have style?

photo ©KeithSpiroPhotography

Xconomy Boston — 

What’s Hot in Boston Biotech? Just about everything—but don’t mistake that for meaning the good times will roll on forever.

As I wrote last week, that was one of the main themes of our latest biotech event at the Broad Institute of MIT and Harvard. Today I’m circling back with the photos so you can get a taste of the action.

Once again, thanks to our attendees for packing the house, and our speakers and moderators for putting on a great show. Great thanks, too, to our event host, Biogen, the Broad Institute for turning over its beautiful auditorium, our national partner Alexandria Real Estate Equities, and to the event sponsors: ALT, Cote Orphan, Fairfax County Economic Development Authority, and Mintz Levin.

Finally, thanks to Keith Spiro of Keith Spiro Photography for these photos. See you all again soon.